Trial Profile
A Phase 2, Multi-center, Open-label, Dose-finding Trial to Investigate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of OPC-41061 in Patients With Chronic Renal Failure Undergoing Hemodialysis or Hemodiafiltration
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Aug 2018
Price :
$35
*
At a glance
- Drugs Tolvaptan (Primary)
- Indications Renal failure
- Focus Therapeutic Use
- Sponsors Otsuka Pharmaceutical
- 01 Aug 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 23 Apr 2014 New trial record